If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-08. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
=== Human civilization: a model for extrapolation === Kardashev poses the following question: "Is it possible to describe the development of a civilization in general terms over large cosmological periods?" Now many of the fundamental parameters that characterize the development of civilization on Earth are growing exponentially. In the field of energy, astronomer Don Goldsmith estimated that the Earth receives about one billionth of the Sun's energy, and that humans use about one millionth of it. So we consume about one millionth of a billionth of the Sun's total energy. Since human expansion is exponential, we can determine how long it will take for humanity to go from Type II to Type III according to Michio Kaku. Thus, the rate of development of our own world remains the only criterion for extrapolating the state of civilizations older than humanity. The same is true for social values and basic needs according to Ashkenazi. Therefore, the time to double technical knowledge is about 10 years, and to double energy output, available reserves, and population is about 25 years. Two scenarios are then possible: spatial expansion or energy stagnation, the latter being possible only for 125 years, according to Kardashev, using the following relationship
== Major leagues == Epstein was first brought up for six games by the Baltimore Orioles in 1966, at the age of 23. After the Orioles tried in vain to convert him to the outfield (they already had Boog Powell at first base), they demoted him to Rochester again. The outspoken Epstein refused to report, going home to California and continuing his schooling instead. He was traded along with Frank Bertaina from the Orioles to the Washington Senators for Pete Richert on 29 May 1967, going from one of the best organizations in baseball to one of the worst. Later that season, in his first at-bat against the Orioles, Epstein hit a grand slam. In 1968 he was fourth in the league in getting hit by pitches HBP (9). In 1969 with the Senators, in only 403 at bats Epstein hit 30 home runs (ninth in the American League), had 85 runs batted in (RBIs), and hit for a .278 batting average (and .347 with runners in scoring position) with an excellent .414 on-base percentage and .551 slugging percentage. He was fourth in the league in hit by pitch (10), and he hit a home run every 13.4 at bats. He was 25th in voting for the American League MVP. This was also the only year in which the reconstituted Senators (now the Texas Rangers) finished above .500. In 1970, he was second in the league in being hit by a pitch (13), while hitting 20 home runs, and leading all AL first basemen in range factor (10.08). In 1969-70, he was managed by Hall of Fame hitting great Ted Williams.
One CMT called COL-3 or metastat has been demonstrated to be a potent MMP inhibitor. COL-3 features a tetracycline scaffold that is unsubstituted on positions C4–C9. Advantages of CMT over conventional tetracyclines are that chronic use does not result in gastrointestinal toxicity and higher plasma levels can be achieved for extended time span reducing administration frequency. The pharmacokinetics of COL-3 has been studied in rats. COL-3 is absorbed slowly from the gastrointestinal tract. 3% are excreted through the urinary tract while 55–66% is excreted in feces. The drug is highly lipophilic and able to cross the blood brain barrier at higher doses. COL-3 accumulates in higher concentration in heart tissue and testis. In clinical trials plasma protein binding has been shown to be high (~94,5%). Most COL-3 binds to serum albumin.
Sources: en.wikipedia.org
Pending the resolution of litigation, the Cherokee Freedman had all rights as full Cherokee Nation citizens, including voting rights and access to tribal services. In early 2011, the tribal district court ruled that the special election in 2007 on the constitutional amendment was unconstitutional, as it excluded Freedmen from voting. The Nation appealed. On August 22, 2011, the Cherokee Supreme Court upheld the results of the 2007 special election. Chuck Trimble, a former executive director of the National Congress of American Indians, characterized the decision as the "Cherokee Dred Scott Decision", for depriving a group of citizenship. At the same time, the Cherokee Supreme Court ordered a special run-off election to be held September 24, 2011 to settle the office of Principal Chief. Earlier voting in this year's election had been so close that the incumbent Chad Smith and challenger Bill John Baker, longtime Cherokee National Council member, had each twice been declared the winner. On September 11, the nation sent letters to Freedmen, notifying them of their loss of citizenship and voting rights. The US Department of Housing and Urban Development froze $33 million in funds to the Cherokee Nation while studying the case, pursuant to a stipulation in the 2008 congressional renewal of Self-Determination Act.
This follows an exchange in the House during PMQs when Starmer, answering a question from the leader of the opposition, Kemi Badenoch, said that "two of her predecessors had convictions for breaking the Covid rules". Although the former Conservative prime ministers, Johnson and Rishi Sunak had received fixed penalty notices for breaking Covid-19 regulations, neither had any criminal convictions. Scottish Finance Secretary Shona Robison delivers the 2024 budget, which includes planned changes to taxation and a pledge to scrap the two child benefit cap in Scotland. Welsh Conservative leader Andrew RT Davies tells BBC News Wales there has been "plotting" among Conservative Senedd members to oust him since April. Secretary of State for Northern Ireland Hilary Benn begins the process of repealing the controversial Legacy Act. 27-year-old Sam Smith is announced as the new leader of Nottinghamshire County Council. Karen Kilgour, leader of Newcastle City Council, faces a vote of no confidence. 5 December – Starmer delivers a major speech in which he sets out six objectives which he says "give the British people the power to hold our feet to the fire"; the objectives cover the economy, housebuilding, the NHS, policing, pre-school education and green energy. Questions are raised over whether Henry Tufnell, the MP for Mid and South Pembrokeshire, gave his parents advanced knowledge of plans to change inheritance tax rules after they transferred ownership of farm land to one of their sons days before the budget.
== Career == She spent the next two years in postdoctoral positions, studying on a 1965–1966 fellowship from the American Association of University Women at the University of California, Berkeley with Melvin Calvin. In 1967, she worked at the Space Sciences Laboratory with Melvin Calvin and A. L. Burlingame. Calvin's lab was developing methods to be used in the analysis of lunar rock samples. Fenselau described an analysis technique for preparing lipid samples from Moon rocks, before actual lunar samples were available for testing.
VR offers several novel control schemes - how the player manipulates their in-game character through the game world and the direction they are looking - compared to the traditional free look or mouselook offered by the traditional KBM or standard controller. Movement and aim may be coupled between the headset and the controllers or may be decoupled, typically with the headset controlling the direction of movement and controller the aim, which generally leads to more immersive experiences. Some VR systems such as the HTC Vive and Oculus offer room scale tracking, which not only incorporate the motions of the player but where they are physically located within a given area and the physical positioning of their body. This allows the player to move around the area as part of the VR experience. Games usually make this an optional experience since not all VR systems support it, and not all players have space to be able to move about. Example of games that support room scale tracking include Job Simulator and Rec Room. When room scale is not available, alternate movement schemes have been developed when character movement is required. A player may be moved automatically by the game as necessary, a player may need to look at a target location and indicate through a control scheme their desire to move their character to that spot, or the player may use more traditional controls such as an analog stick or keyboard presses to move their character.
Sources: en.wikipedia.org
==== Alcohol-ether treatment ==== This treatment follows the similar treatment of the PEG solution but instead of replacing the cells with another solution, the cells are replaced with alcohol and when the alcohol evaporates the cell and overall object is dehydrated. As a volatile solvent treatment option, the impact on the health and safety on the workplace must be considered.
==== Chemically induced ==== The chemical compounds aloxan and streptozotocin (STZ) are commonly used to induce diabetes and destroy β-cells in mouse/rat animal models. In both cases, it is a cytotoxic analog of glucose that passes through GLUT2 transport and accumulates in β-cells, causing their destruction. The chemically induced destruction of β-cells leads to decreased insulin production, hyperglycemia, and weight loss in the experimental animal. The animal models prepared in this way are suitable for research into blood sugar-lowering drugs and therapies (e.g., for testing new insulin preparations). They are also the most commonly used genetically induced T1D model is the so-called AKITA mouse (originally C57BL/6NSIc mouse). The development of diabetes in AKITA mice is caused by a spontaneous point mutation in the Ins2 gene, which is responsible for the correct composition of insulin in the endoplasmic reticulum. Decreased insulin production is then associated with hyperglycemia, polydipsia, and polyuria. If severe diabetes develops within 3–4 weeks, AKITA mice survive no longer than 12 weeks without treatment intervention. The description of the etiology of the disease shows that, unlike spontaneous models, the early stages of the disease are not accompanied by insulitis. AKITA mice are used to test drugs targeting endoplasmic reticulum stress reduction, to test islet transplants, and to study diabetes-related complications such as nephropathy, sympathetic autonomic neuropathy, and vascular disease. for testing transplantation therapies.
==== Convergent evolution ==== Color change is widespread in ectotherms including anoles, frogs, mollusks, many fish, insects, and spiders. The mechanism behind this color change can be either morphological or physiological. Morphological change is the result of a change in the density of pigment containing cells and tends to change over longer periods of time. Physiological change, the kind observed in cephalopod lineages, is typically the result of the movement of pigment within the chromatophore, changing where different pigments are localized within the cell. This physiological change typically occurs on much shorter timescales compared to morphological change. Cephalopods have a rare form of physiological color change which utilizes neural control of muscles to change the morphology of their chromatophores. This neural control of chromatophores has evolved convergently in both cephalopods and teleosts fishes.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.